サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1775012

メトトレキサート製剤の世界市場

Methotrexate Drugs

出版日
ページ情報
英文 564 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
メトトレキサート製剤の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 564 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

メトトレキサート製剤の世界市場は2030年までに13億米ドルに達する

2024年に12億米ドルと推定されるメトトレキサート製剤の世界市場は、2024～2030年の分析期間においてCAGR 1.9%で成長し、2030年には13億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乾癬は、CAGR 2.5%を記録し、分析期間終了時には5億9,560万米ドルに達すると予測されます。関節リウマチ分野の成長率は、分析期間中CAGR 1.0%と推定されます。

米国市場は3億2,180万米ドルと推定、中国はCAGR 3.8％で成長予測

米国のメトトレキサート製剤市場は、2024年には3億2,180万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを3.8%として、2030年までに2億4,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と1.4%と予測されています。欧州では、ドイツがCAGR約0.9%で成長すると予測されています。

世界のメトトレキサート製剤市場- 主要動向と促進要因まとめ

メトトレキサート製剤とは何か？

メトトレキサートは強力な代謝拮抗薬であり、元々はがん治療のために開発された抗葉酸薬ですが、現在では複数の治療分野で広く使用されています。メトトレキサートはジヒドロ葉酸還元酵素（DHFR）を阻害することにより機能し、DNA合成と細胞複製を阻害します。メトトレキサートは、白血病、リンパ腫、骨肉腫などの特定のがんに対する化学療法レジメンの要であることに変わりはないが、免疫抑制作用があるため、自己免疫疾患や炎症性疾患の治療にも広く使用されています。メトトレキサートは、関節リウマチ、乾癬、乾癬性関節炎、クローン病、全身性エリテマトーデス（SLE）に低用量から処方されるのが一般的です。

メトトレキサートは、経口剤と非経口剤（注射剤と皮下注剤）の両方があり、臨床場面において柔軟な投与が可能です。自己免疫疾患では、特に関節リウマチの治療において第一選択薬またはアンカー薬とされることが多く、生物学的製剤や他の疾患修飾性抗リウマチ薬（DMARDs）と併用されることが多いです。がん領域では、毒性を緩和するためにロイコボリンレスキューと一緒に高用量で投与されます。メトホルミンには免疫反応を調節する作用があり、費用対効果も高いため、開発途上国、先進国双方のヘルスケアシステムでその役割が確固たるものとなっています。より新しい標的治療薬にもかかわらず、メトトレキサートは、その長い実績、確立された有効性、多くの臨床ガイドラインに含まれていることから、好まれる薬剤であり続けています。

メトトレキサートの使用を形成する市場力学と進化する動向とは？

メトトレキサート製剤市場は、治療プロトコルの変化、自己免疫疾患の有病率の増加、ドラッグデリバリーの革新に対応して進化しています。自己免疫疾患や慢性炎症性疾患が世界的に増加する中、メトトレキサートのような信頼性が高く手頃な価格のDMARDsに対する需要は着実に拡大しています。自動注射器やプレフィルドシリンジなどの非経口デリバリーシステムの技術的進歩は、患者のコンプライアンスを向上させ、外来や在宅医療における注射用メトトレキサートの使用を拡大しています。これらの技術革新は、長期にわたるアドヒアランスが疾患管理に不可欠な関節リウマチのような慢性治療において特に重要です。

一方、バイオシミラーやジェネリック医薬品の開発は、特に医療制度がコスト抑制を優先する新興国市場において競争を激化させています。アジア太平洋、ラテンアメリカ、東欧の一部では、メトトレキサートのジェネリック医薬品の存在感が高まっており、市場浸透を促すと同時に治療をより身近なものにしています。FDAやEMAなどの規制当局もジェネリック医薬品やバイオシミラーの承認経路を合理化しており、国内外のメーカーにチャンスをもたらしています。さらに、メトトレキサートはTNF阻害剤やJAK阻害剤などとの併用療法で臨床効果を最大化し、病勢進行を最小化するための研究が進められています。メトトレキサートはまた、有効性を維持しながら毒性を軽減することを目的とした新規適応や用量最適化試験でも評価されています。

メトトレキサート製剤市場の成長はいくつかの要因によってもたらされる

メトトレキサート製剤市場の成長は、関節リウマチ、乾癬、炎症性腸疾患などの自己免疫疾患の罹患率の上昇など、いくつかの要因によって牽引されています。慢性炎症疾患に罹患しやすい高齢化社会は、市場の拡大をさらに後押ししています。がん領域では、メトトレキサートは、特に小児白血病や希少がんに対する多剤併用化学療法レジメンの重要な一部であり、標的治療薬の台頭にもかかわらず、その関連性を維持しています。

低コストのジェネリック製剤が入手しやすくなったことで、特に中低所得国でのアクセスが大幅に拡大し、治療カテゴリー全体で広く採用されるようになりました。さらに、皮下自動注射器や徐放性注射剤など、患者にやさしい投与形態の出現が、長期療法を必要とする患者への普及を後押ししています。好意的な償還政策、各国の必須医薬品リストへの掲載、慢性疾患管理に対する世界の保健機関からの支援も重要な役割を果たしています。さらに、自己免疫疾患の早期かつ積極的な管理に対する医療従事者や患者の意識の高まりが、メトトレキサートの基礎治療としての地位を強化しています。これらの要因が相まって、メトトレキサート製剤市場は当面堅調な成長を維持すると予想されます。

セグメント

適応症（乾癬、関節リウマチ、がん、その他の適応症）、薬剤タイプ（ブランド、ジェネリック）、剤形（錠剤、液剤、注射剤）、投与経路（経口、皮下、筋肉内、静脈内）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例

  • Accord Healthcare Inc.
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Hikma Pharmaceuticals PLC
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG（Sandoz）
  • Pfizer Inc.
  • Pharmascience Inc.
  • Sandoz Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32123

Global Methotrexate Drugs Market to Reach US$1.3 Billion by 2030

The global market for Methotrexate Drugs estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Psoriasis, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$595.6 Million by the end of the analysis period. Growth in the Rheumatoid arthritis segment is estimated at 1.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$321.8 Million While China is Forecast to Grow at 3.8% CAGR

The Methotrexate Drugs market in the U.S. is estimated at US$321.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$248.7 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Methotrexate Drugs Market - Key Trends & Drivers Summarized

What Are Methotrexate Drugs and How Are They Used Across Therapeutic Areas?

Methotrexate is a potent antimetabolite and antifolate drug originally developed for cancer treatment but now widely used across multiple therapeutic areas. It functions by inhibiting the enzyme dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and cell replication. While it remains a cornerstone in chemotherapy regimens for certain cancers such as leukemia, lymphoma, and osteosarcoma, methotrexate has found extensive use in the management of autoimmune and inflammatory disorders due to its immunosuppressive properties. It is commonly prescribed in low doses for rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and systemic lupus erythematosus (SLE).

Methotrexate is available in both oral and parenteral formulations (injectable and subcutaneous), offering dosing flexibility across clinical scenarios. In autoimmune diseases, it is often considered a first-line or anchor drug, particularly in the treatment of rheumatoid arthritis, where it is frequently combined with biologics or other disease-modifying antirheumatic drugs (DMARDs). In oncology, it is administered at high doses with leucovorin rescue to mitigate toxicity. The drug’s ability to modulate immune responses and its cost-effectiveness have cemented its role in both developing and developed healthcare systems. Despite newer targeted therapies, methotrexate continues to be a preferred agent due to its long track record, established efficacy, and inclusion in numerous clinical guidelines.

What Are the Market Dynamics and Evolving Trends Shaping Methotrexate Use?

The methotrexate drugs market is evolving in response to changing therapeutic protocols, increasing prevalence of autoimmune diseases, and innovations in drug delivery. With autoimmune and chronic inflammatory disorders on the rise globally, the demand for reliable and affordable DMARDs like methotrexate is expanding steadily. Technological advances in parenteral delivery systems, such as autoinjectors and prefilled syringes, are enhancing patient compliance and expanding the use of injectable methotrexate in outpatient and home-care settings. These innovations are particularly significant for chronic therapy in conditions like rheumatoid arthritis, where long-term adherence is critical for disease management.

Meanwhile, biosimilar and generic drug development is intensifying competition, especially in emerging markets where healthcare systems prioritize cost containment. The growing presence of methotrexate generics in Asia-Pacific, Latin America, and parts of Eastern Europe is making treatment more accessible while stimulating market penetration. Regulatory agencies such as the FDA and EMA have also streamlined approval pathways for generics and biosimilars, creating opportunities for local and international manufacturers. In addition, research is exploring the use of methotrexate in combination therapies, such as with TNF inhibitors or JAK inhibitors, to maximize clinical benefit and minimize disease progression. The drug is also being evaluated in novel indications and dose-optimization studies aimed at reducing toxicity while maintaining efficacy.

The Growth in the Methotrexate Drugs Market is Driven by Several Factors

The growth in the methotrexate drugs market is driven by several factors, including the rising incidence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases, which collectively contribute to increasing global demand for immunomodulatory treatments. The aging population, which is more susceptible to chronic inflammatory conditions, further supports market expansion. In oncology, methotrexate remains a vital part of multi-agent chemotherapy regimens, especially for pediatric leukemias and rare cancers, maintaining its relevance despite the rise of targeted therapies.

The increased availability of low-cost generic formulations has significantly broadened access, particularly in low- and middle-income countries, enabling widespread adoption across therapeutic categories. Additionally, the emergence of patient-friendly delivery formats, such as subcutaneous autoinjectors and sustained-release injectables, is driving uptake among patients requiring long-term therapy. Favorable reimbursement policies, inclusion in national essential medicines lists, and support from global health organizations for chronic disease management also play a key role. Furthermore, rising awareness among healthcare providers and patients about early and aggressive management of autoimmune diseases is reinforcing methotrexate’s position as a foundational treatment. These combined drivers are expected to sustain robust growth in the methotrexate drugs market over the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Methotrexate Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Psoriasis, Rheumatoid arthritis, Cancer, Other indications); Drug Type (Branded, Generic); Drug Form (Tablet, Liquid, Injectable); Administration Route (Oral, Subcutaneous, Intramuscular, Intravenous); Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Accord Healthcare Inc.
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Hikma Pharmaceuticals PLC
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Pharmascience Inc.
  • Sandoz Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Methotrexate Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Autoimmune Diseases Spurs Demand for Methotrexate-Based Therapies
    • Growing Incidence of Cancer Worldwide Throws the Spotlight on Methotrexate as a Key Chemotherapeutic Agent
    • Rising Preference for Low-Cost Generic Oncology Drugs Expands Addressable Market Opportunity for Methotrexate
    • Strategic Collaborations Between Pharma Companies and CROs Drive Clinical Research and Methotrexate Drug Pipeline Expansion
    • Advancements in Drug Delivery Mechanisms Strengthen Business Case for Injectable Methotrexate Formulations
    • Surge in Pediatric Applications for Juvenile Arthritis Propels Growth in Specialized Methotrexate Dosage Forms
    • Inclusion of Methotrexate in WHO's List of Essential Medicines Generates Demand Across Developing Markets
    • Growing Emphasis on Early RA Diagnosis and Intervention Drives Adoption of Methotrexate as First-Line Therapy
    • Health Insurance Coverage Expansion in Emerging Economies Sustains Growth in Methotrexate Treatment Uptake
    • Development of Biosimilar and Bioequivalent Methotrexate Formulations Accelerates Market Penetration
    • Rising Awareness Among Physicians and Patients Throws the Spotlight on Methotrexate Treatment Benefits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Methotrexate Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Methotrexate Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Methotrexate Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Methotrexate Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rheumatoid arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rheumatoid arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Rheumatoid arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Retail pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Online pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Online pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Online pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Liquid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • JAPAN
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Japan 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • CHINA
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 98: China Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: China 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • EUROPE
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Methotrexate Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Methotrexate Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Europe Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Europe 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • FRANCE
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 131: France Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 143: France Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: France Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: France 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • GERMANY
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 158: Germany Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Germany Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Germany 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 173: Italy Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Italy Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Italy 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 176: UK Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: UK 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 179: UK Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 182: UK Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 188: UK Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UK Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UK 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 191: Spain Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Spain Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Spain 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 203: Spain Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Spain Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Spain 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 206: Russia Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Russia Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Russia 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 218: Russia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Russia Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Russia 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Europe Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Europe 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Europe Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Europe 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Asia-Pacific Historic Review for Methotrexate Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 254: Australia Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Australia Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Australia 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 266: Australia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Australia Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Australia 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • INDIA
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 269: India Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: India Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: India 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 272: India Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 275: India Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 281: India Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: India Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: India 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 284: South Korea Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: South Korea Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: South Korea 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 296: South Korea Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: South Korea Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: South Korea 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Asia-Pacific Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Asia-Pacific Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 314: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 315: Latin America Historic Review for Methotrexate Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Latin America 15-Year Perspective for Methotrexate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Latin America Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Latin America 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 332: Argentina Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Argentina Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Argentina 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 344: Argentina Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Argentina Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Argentina 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 347: Brazil Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Brazil Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Brazil 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 359: Brazil Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Brazil Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Brazil 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 362: Mexico Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Mexico Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Mexico 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 374: Mexico Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Mexico Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Mexico 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Latin America Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Latin America 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Latin America Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Latin America 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 392: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 393: Middle East Historic Review for Methotrexate Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Middle East 15-Year Perspective for Methotrexate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Middle East Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 409: Middle East 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 410: Iran Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Iran Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 412: Iran 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 422: Iran Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Iran Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 424: Iran 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 425: Israel Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Israel Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 427: Israel 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 437: Israel Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Israel Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 439: Israel 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Saudi Arabia Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 442: Saudi Arabia 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 453: Saudi Arabia Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 454: Saudi Arabia 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 455: UAE Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 456: UAE Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 457: UAE 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 467: UAE Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 468: UAE Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 469: UAE 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Rest of Middle East Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 472: Rest of Middle East 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Rest of Middle East Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 484: Rest of Middle East 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030
  • AFRICA
    • Methotrexate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 485: Africa Recent Past, Current & Future Analysis for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Africa Historic Review for Methotrexate Drugs by Indication - Psoriasis, Rheumatoid arthritis, Cancer and Other indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 487: Africa 15-Year Perspective for Methotrexate Drugs by Indication - Percentage Breakdown of Value Sales for Psoriasis, Rheumatoid arthritis, Cancer and Other indications for the Years 2015, 2025 & 2030
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Methotrexate Drugs by Administration Route - Oral, Subcutaneous, Intramuscular and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Methotrexate Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous, Intramuscular and Intravenous for the Years 2015, 2025 & 2030
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Methotrexate Drugs by Distribution Channel - Hospital pharmacies, Retail pharmacies and Online pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Methotrexate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Online pharmacies for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Methotrexate Drugs by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Methotrexate Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2015, 2025 & 2030
    • TABLE 497: Africa Recent Past, Current & Future Analysis for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 498: Africa Historic Review for Methotrexate Drugs by Drug Form - Tablet, Liquid and Injectable Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 499: Africa 15-Year Perspective for Methotrexate Drugs by Drug Form - Percentage Breakdown of Value Sales for Tablet, Liquid and Injectable for the Years 2015, 2025 & 2030

IV. COMPETITION